Imiquimod
FDA Approved
Description
Imiquimod is a topical immune response modifier used to treat superficial basal cell carcinoma, actinic keratosis, and external genital warts. It can be used for benign skin lesions including certain benign tumors of the eyelid epidermis. The drug works by stimulating local immune responses through toll-like receptor 7 activation.
Indications & Therapeutic Use
Superficial basal cell carcinoma, Actinic keratosis, External genital warts, Benign epidermal lesions
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Imiquimod
| Generic Name | Imiquimod |
| Brands | 1 brand available |
| Active Ingredient | Imiquimod |
| Drug Class | Superficial basal cell carcinoma |
| Manufacturer | 3M Pharmaceuticals |
| Dosage Forms | Topical cream 5% |
| Medical Code | D06BB10 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes